Adding pamrevlumab to standard chemotherapy did not improve survival in patients with locally advanced pancreatic cancer ...

It develops Zunsemetinib (ATI-450), an MK2 inhibitor which is under Phase 1b/2 trials for the treatment of metastatic breast and pancreatic cancer; ATI-1777, a soft JAK 1/3 inhibitor, completed ...

Today the American Cancer Society called out the need for more progress on pancreatic cancer, citing it as the third-leading cause of cancer-related death in the U.S. Their annual report also includes ...

Background: To estimate the global burden of pancreatic cancer in 2019 and 2021 including incidence, mortality, and disability-adjusted-life-years (DALYs). Methods: Data on pancreatic cancer incidence ...

We work right across the cancer research pathway with strengths ranging from cell biology to healthcare research. We aim to nurture the thought leaders of today and tomorrow through the provision of ...

What is a 5-year relative survival rate? Where do these numbers come from? 5-year relative survival rates for pancreatic cancer Understanding the numbers Keep in mind that survival rates are estimates ...

Background Patients with type 2 diabetes mellitus (T2DM) have higher pancreatic cancer (PC) risk. While aspirin has chemopreventive effects on digestive cancers, its effect on PC among patients with ...

More information: Bharti Garg et al, MICAL2 Promotes Pancreatic Cancer Growth and Metastasis, Cancer Research (2025). DOI: 10.1158/0008-5472.CAN-24-0744 Journal information: Cancer Research ...

An enzyme called MICAL2 promotes tumor growth and metastasis in the most common form of pancreatic cancer, according to a new study. Pancreatic cancer kills 50,000 people each year, according to ...

UC San Diego’s latest study reveals MICAL2 as a critical factor in pancreatic cancer progression, offering new avenues for treatment through targeted therapies that could inhibit this enzyme and slow ...